102 related articles for article (PubMed ID: 7830266)
1. Rationally designed analogues of tamoxifen with improved calmodulin antagonism.
Hardcastle IR; Rowlands MG; Houghton J; Parr IB; Potter GA; Jarman M; Edwards KJ; Laughton CA; Trent JO; Neidle S
J Med Chem; 1995 Jan; 38(2):241-8. PubMed ID: 7830266
[TBL] [Abstract][Full Text] [Related]
2. Homologs of idoxifene: variation of estrogen receptor binding and calmodulin antagonism with chain length.
Hardcastle IR; Rowlands MG; Grimshaw RM; Houghton J; Jarman M
J Med Chem; 1996 Feb; 39(4):999-1004. PubMed ID: 8632423
[TBL] [Abstract][Full Text] [Related]
3. Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; correlations with cytotoxicity.
Rowlands MG; Parr IB; McCague R; Jarman M; Goddard PM
Biochem Pharmacol; 1990 Jul; 40(2):283-9. PubMed ID: 2165403
[TBL] [Abstract][Full Text] [Related]
4. Antagonism of estrogen receptor and calmodulin association by antiestrogens is not dependent on an interaction with calmodulin.
Rowlands MG; Grimshaw R; Jarman M; Bouhoute A; Leclercq G
Biochem Pharmacol; 1997 Jan; 53(2):241-4. PubMed ID: 9037257
[TBL] [Abstract][Full Text] [Related]
5. Evidence that tamoxifen binds to calmodulin in a conformation different to that when binding to estrogen receptors, through structure-activity study on ring-fused analogues.
McCague R; Rowlands MG; Grimshaw R; Jarman M
Biochem Pharmacol; 1994 Oct; 48(7):1355-61. PubMed ID: 7945433
[TBL] [Abstract][Full Text] [Related]
6. Comparison between inhibition of protein kinase C and antagonism of calmodulin by tamoxifen analogues.
Rowlands MG; Budworth J; Jarman M; Hardcastle IR; McCague R; Gescher A
Biochem Pharmacol; 1995 Aug; 50(5):723-6. PubMed ID: 7669076
[TBL] [Abstract][Full Text] [Related]
7. A molecular modeling study of the interactions between the antiestrogen drug tamoxifen and several derivatives, and the calcium-binding protein calmodulin.
Edwards KJ; Laughton CA; Neidle S
J Med Chem; 1992 Jul; 35(15):2753-61. PubMed ID: 1322985
[TBL] [Abstract][Full Text] [Related]
8. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
Sharp SY; Rowlands MG; Jarman M; Kelland LR
Br J Cancer; 1994 Sep; 70(3):409-14. PubMed ID: 8080723
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of protein kinase C and calmodulin by the geometric isomers cis- and trans-tamoxifen.
O'Brian CA; Ioannides CG; Ward NE; Liskamp RM
Biopolymers; 1990 Jan; 29(1):97-104. PubMed ID: 2158363
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships of calmodulin antagonism by triphenylethylene antiestrogens.
Barrera G; Screpanti I; Paradisi L; Parola M; Ferretti C; Vacca A; Farina A; Dianzani MU; Frati L; Gulino A
Biochem Pharmacol; 1986 Sep; 35(17):2984-6. PubMed ID: 3017367
[No Abstract] [Full Text] [Related]
11. Calmodulin antagonism and growth-inhibiting activity of triphenylethylene antiestrogens in MCF-7 human breast cancer cells.
Gulino A; Barrera G; Vacca A; Farina A; Ferretti C; Screpanti I; Dianzani MU; Frati L
Cancer Res; 1986 Dec; 46(12 Pt 1):6274-8. PubMed ID: 3022916
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships for triphenylethylene antiestrogens on hepatic phase-I and phase-II enzyme expression.
Nuwaysir EF; Dragan YP; McCague R; Martin P; Mann J; Jordan VC; Pitot HC
Biochem Pharmacol; 1998 Aug; 56(3):321-7. PubMed ID: 9744569
[TBL] [Abstract][Full Text] [Related]
13. Effects of felodipine (a dihydropyridine calcium channel blocker) and analogues on calmodulin-dependent enzymes.
Walsh MP; Sutherland C; Scott-Woo GC
Biochem Pharmacol; 1988 Apr; 37(8):1569-80. PubMed ID: 2833901
[TBL] [Abstract][Full Text] [Related]
14. Pyrrolo[2,3-d]pyrimidines as inhibitors of cAMP-phosphodiesterase. Structure-activity relationship.
Klumpp S; Frey M; Kleefeld G; Sauer A; Eger K
Biochem Pharmacol; 1989 Mar; 38(6):949-53. PubMed ID: 2539163
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase.
Lam HY
Biochem Biophys Res Commun; 1984 Jan; 118(1):27-32. PubMed ID: 6320825
[TBL] [Abstract][Full Text] [Related]
16. Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer.
Chander SK; McCague R; Luqmani Y; Newton C; Dowsett M; Jarman M; Coombes RC
Cancer Res; 1991 Nov; 51(21):5851-8. PubMed ID: 1933854
[TBL] [Abstract][Full Text] [Related]
17. Antiestrogen basicity--activity relationships: a comparison of the estrogen receptor binding and antiuterotrophic potencies of several analogues of (Z)-1,2-diphenyl-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-butene (tamoxifen, Nolvadex) having altered basicity.
Robertson DW; Katzenellenbogen JA; Hayes JR; Katzenellenbogen BS
J Med Chem; 1982 Feb; 25(2):167-71. PubMed ID: 7057423
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of basic side chain derivatives of Analog II as pure antiestrogens and antitumor agents.
Magarian RA; Avor KS; Overacre LB; Kunchandy J; Paxton TR
Anticancer Drug Des; 1995 Jun; 10(4):311-31. PubMed ID: 7786397
[TBL] [Abstract][Full Text] [Related]
19. Polymyxin B is a selective and potent antagonist of calmodulin.
Hegemann L; van Rooijen LA; Traber J; Schmidt BH
Eur J Pharmacol; 1991 May; 207(1):17-22. PubMed ID: 1915592
[TBL] [Abstract][Full Text] [Related]
20. New milrinone analogues: in vitro study of structure-activity relationships for positive inotropic effect, antagonism towards endogenous adenosine, and inhibition of cardiac type III phosphodiesterase.
Floreani M; Fossa P; Gessi S; Mosti L; Borea PA; Dorigo P
Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb; 367(2):109-18. PubMed ID: 12595951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
